Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19534750 | 0.79 | — | — | |
| SCHEMBL11037870 | 0.75 | — | — | |
| SCHEMBL5815964 | 0.75 | — | — | |
| SCHEMBL27518236 | 0.73 | POLB (0.35) | — | |
| Ammonia Solution, Strong SCHEMBL28154471 | 0.73 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL28961166 | 0.73 | POLB (0.35) | — | |
| SCHEMBL29152644 | 0.73 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL28326518 | 0.73 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL11385959 | 0.72 | CHRNB2 (0.31) | — | |
| SCHEMBL27368435 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103958495-A | Novel compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA | 2014-07-30 | — | — | CN | claimed |
| CN-111212842-B | Vasopressin receptor antagonists and products and methods related thereto | 布莱克索恩治疗公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-111212842-A | Vasopressin receptor antagonists and products and methods related thereto | 布莱克索恩治疗公司 | 2020-05-29 | — | — | CN | disclosed |
| CN-103958495-B | The compound of conditioning agent as GPR-119 | 理森制药股份公司 | 2018-06-22 | — | — | CN | disclosed |
| US-9777018-B2 | Compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| CN-106660950-A | Use of CXCR2 antagonists for the prevention and/or treatment of chemotherapy-induced peripheral neuropathy (CIPN) | 葛兰素史密斯克莱知识产权发展有限公司 | 2017-05-10 | — | — | CN | disclosed |
| US-20150361092-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2015-12-17 | — | — | US | disclosed |
| CN-103958495-A | Novel compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA | 2014-07-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361092-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | GPR119, GPR39, GPBAR1 | CFTR 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.